Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dalbavancin: a novel antimicrobial.

A Y Chen1, M J Zervos, J A Vazquez

  • 1Wayne State University School of Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI 48202, USA.

International Journal of Clinical Practice
|March 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved Metal Cation Optosensing Membranes through the Incorporation of Sulphated Polysaccharides.

Molecules (Basel, Switzerland)·2022
Same author

Study of the immunologic response of marine-derived collagen and gelatin extracts for tissue engineering applications.

Acta biomaterialia·2022
Same author

Words matter: a randomized controlled study evaluating the impact of decision-framing on treatment preferences in adults with psoriasis and psoriatic arthritis.

The British journal of dermatology·2020
Same author

Epidemiology, molecular characterisation and antimicrobial susceptibility of <i>Neisseria gonorrhoeae</i> isolates in Madrid, Spain, in 2016.

Epidemiology and infection·2019
Same author

[From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2019
Same author

Scale law of complex deformation transitions of nanotwins in stainless steel.

Nature communications·2019

Dalbavancin offers a new, once-weekly treatment option for Gram-positive bacterial infections. A Phase III trial showed it is as effective and safe as linezolid for complicated skin infections.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Microbiology

Background:

  • Rising incidence of serious Gram-positive bacterial infections.
  • Increasing costs and challenges associated with parenteral antimicrobial administration.
  • Need for novel antibiotics with improved dosing and efficacy.

Purpose of the Study:

  • To evaluate the efficacy and safety of dalbavancin compared to linezolid.
  • To assess dalbavancin as a novel treatment for Gram-positive infections.
  • To determine the suitability of dalbavancin for complicated skin and skin structure infections.

Main Methods:

  • A large, multicenter, pivotal Phase III clinical trial.
  • Inclusion of 854 patients with complicated skin and skin structure infections.

Related Experiment Videos

  • Comparison of 1-2 doses of dalbavancin versus linezolid.

    • Main Results:

    • Dalbavancin demonstrated non-inferiority to linezolid.
    • A comparable safety profile was observed between dalbavancin and linezolid.
    • Dalbavancin showed broad-spectrum activity against Gram-positive pathogens.

    Conclusions:

    • Dalbavancin is a valuable addition to the treatment options for Gram-positive cocci infections.
    • Its unique pharmacokinetic profile and ease of use enhance its therapeutic potential.
    • Dalbavancin provides an effective and safe alternative to existing treatments.